NCT04710576Phase 2Recruiting

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

Study sponsor: Syndax Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-04-07Actual
Enrollment · participants296Estimated
Source updated2026-06-16Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Participant count type changed

Before: Actual. After: Estimated.

Enrollment · participant count changed

Before: 241 participants (actual). After: 296 participants (planned).

Recruitment status changed

Before: Active not recruiting. After: Recruiting.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview